在IMP金属-β-乳酸酶的临床变体中,抑制剂亲和力不同:对抑制剂设计的分析和影响
Caitlyn A Thomas1, John Paul Alao1, Thomas Smisek2
1Department of Chemistry and Biochemistry, Miami University, Oxford, Ohio 45056, United States.
ACS infectious diseases
|July 24, 2025
概括
两种金属β-乳糖酶 (MBL) 抑制剂RPX 7546和D-CS319对IMP-1及其变种IMP-78进行了测试. D-CS319有效地抑制了两者,而RPX 7546对IMP-78.8的影响较小.
科学领域:
- 生物化学 生化学
- 微生物学 微生物学
- 药物发现 药物发现 药物发现
背景情况:
- 抗β-乳酸胺的细菌感染构成了全球健康威胁.
- 金属β-乳酸酶 (MBLs) 是关键的酶,通过化β-乳酸抗生素来赋予耐药性.
- 伊米酶 (IMP) 是一种临床显著的MBL,像IMP-78这样的变体显示出增强的卡巴酶活性.
研究的目的:
- 研究两种MBL抑制剂RPX 7546和D-CS319对IMP-1及其变体IMP-78.8的抑制机制.
- 了解IMP-78中的酶进化如何影响抑制剂疗效.
- 评估这些抑制剂对抗MBL介导耐药性的潜力.
主要方法:
- 分析和生化实验的结合.
- 在模型中,以阐明抑制机制.
- 对IMP-1和IMP-78.8的抑制剂活性进行比较分析.
主要成果:
- 与IMP-1相比,RPX 7546对IMP-78的疗效有所降低.
- D-CS319对IMP-1和IMP-78.8均表现出一致且有效的抑制作用.
- 抑制剂有效性的差异与IMP-78.8的进化适应相关.
结论:
- 作为一种广泛的MBL抑制剂,D-CS319显示出对野生类型和变种酶有效的承诺.
- RPX 7546的疗效受到酶变异特异性结构变化的影响.
- 对针对酶变异的MBL抑制剂的进一步研究对于临床应用至关重要.
更多相关视频
08:06The Use of a β-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions
Published on: February 1, 2018
9.1K
07:54Analysis of AtHIRD11 Intrinsic Disorder and Binding Towards Metal Ions by Capillary Gel Electrophoresis and Affinity Capillary Electrophoresis
Published on: August 22, 2018
6.1K
相关概念视频
Enzyme Inhibition
79.6K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
79.6K
Enzymes
82.7K
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
82.7K
Antimicrobial Proteins
5.4K
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
5.4K
Development of Antibiotic Resistance
207
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
207
Combined Effects of Drugs: Synergism
4.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.8K
Ligand Binding and Linkage
4.9K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.9K
